Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Novel CDK 4/6 Inhibitor Explored in Premenopausal Breast Cancer Setting

May 19th 2016

Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.

Long-Term Data Uphold Neoadjuvant Pertuzumab Benefit in HER2+ Breast Cancer

May 19th 2016

A 5-year follow-up of the phase II NeoSphere trial confirmed that patients with HER2-positive breast cancer receiving a 3-drug neoadjuvant pertuzumab regimen had better outcomes compared with patients receiving trastuzumab and docetaxel.

Ribociclib Improves PFS in Phase III Breast Cancer Study

May 19th 2016

The combination of the CDK4/6 inhibitor ribociclib and letrozole significantly improved progression-free survival compared with letrozole alone for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Arnedos on the POP Randomized Trial for Early Breast Cancer

May 16th 2016

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de CancÃ©rologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

May 13th 2016

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

Perou Shares How Deeper Sequencing of Genome Helps Define, Treat Breast Cancer Subtypes

April 28th 2016

Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.

Dr. Partridge on PGD in Young Patients With Breast Cancer

April 28th 2016

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.

Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer

April 19th 2016

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

Frontline Palbociclib Extends PFS in Phase III Breast Cancer Study

April 19th 2016

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival for the frontline combination of palbociclib and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer

April 18th 2016

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation

April 18th 2016

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer

April 18th 2016

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo

April 18th 2016

A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.

Early-Stage Therapies Rapidly Evolving in Breast Cancer

April 13th 2016

Early intervention has increasingly become the new standard of care for many patients with breast cancer, with an ever-growing collection of phase III trials currently exploring several novel or improved approaches.

Charles Perou on Biomarker Assay Use in ASCO Breast Cancer Guideline

April 8th 2016

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

April 4th 2016

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

NCCN Refines Recommendations for Breast Cancer Care

April 2nd 2016

At the 2016 NCCN Annual Conference, William J. Gradishar, MD, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

April 1st 2016

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Neratinib Application Delayed for HER2+ Breast Cancer

March 30th 2016

Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.

Dr. Van Zee on Nomograms for Patients With DCIS

March 30th 2016

Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).